Advertisement

International Journal of Clinical Pharmacy

, Volume 37, Issue 2, pp 289–291 | Cite as

Secondary acute myeloid leukemia arising early after cyclophosphamide treatment

  • Hayretdin KokluEmail author
  • Abdurrahman Tufan
  • Yusuf Erkul
  • Nalan Akyurek
  • Ramazan Civelek
Case Report

Abstract

Background Acute myeloid leukemia (AML) can develop secondary to drug treatment. This phenomenon has been placed under the title “Therapy Related Acute Myeloid Leukemias and Myelodysplastic Syndromes” in the WHO classification of AML. Cyclophosphamide, which is used in various malignancies and rheumatological diseases, is an alkylating agent that plays a significant role in therapy related AML. Case description A patient treated with cyclophosphamide due to vasculitis, subsequently developed AML months after treatment. Conclusion Cyclophosphamide related AML is seen, in most cases, many years after exposure to the drug. The significance of this report lies in the fact that, to our knowledge, this is the most rapidly arising case of cyclophosphamide related AML.

Keywords

Acute myeloid leukemia Cyclophosphamide Vasculitis 

Notes

Funding

None.

Conflicts of interest

None.

References

  1. 1.
    Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMedGoogle Scholar
  2. 2.
    Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62:9–21.CrossRefPubMedGoogle Scholar
  3. 3.
    Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica. 1999;84:937–45.PubMedGoogle Scholar
  4. 4.
    de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Langford CA. Complications of cyclophosphamide therapy. Eur Arch Otorhinolaryngol. 1997;254:65–72.CrossRefPubMedGoogle Scholar
  6. 6.
    National Institutes of Health, National Cancer Institute. Adult Acute Myeloid Leukemia Treatment (PDQ®), Alkylating agent-related acute myeloid leukemia and myelodysplastic syndromes (updated 28 March 2014; cited 23 Dec 2014) (about 12 screens). http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/healthprofessional/page2#Section_139.
  7. 7.
    Mahr A, Heijl C, Le Guenno G. Faurschou M.ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol. 2013;27:45–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener’s granulomatosis. J Rheumatol. 2008;35:11–3.PubMedGoogle Scholar
  9. 9.
    Pedersen-Bjergaard J, Specht L, Larsen SO, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin’s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 1987;8550:83–8.CrossRefGoogle Scholar
  10. 10.
    Smith RE. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer. 2003;4:273–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Safaa M. Ramadan, Tamer M Fouad, Valentina Summa, Syed KH Hasan, and Francesco Lo-Coco Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica. 2012;97:805–17.CrossRefGoogle Scholar
  12. 12.
    Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52.CrossRefPubMedGoogle Scholar
  13. 13.
    Mani D, Dorer RK, Aboulafia DM. Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma. 2009;9:316–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Park TS, Cheong JW, Song J, Choi JR. Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia. Leuk Res. 2009;33:1001–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Bloomfield CD, Archer KJ, Mrózek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:362–78.CrossRefPubMedGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  • Hayretdin Koklu
    • 1
    Email author
  • Abdurrahman Tufan
    • 2
  • Yusuf Erkul
    • 4
  • Nalan Akyurek
    • 3
  • Ramazan Civelek
    • 1
  1. 1.Ic Hastaliklari ABDGazi Universitesi HastanesiBesevler, AnkaraTurkey
  2. 2.Division of Rheumatology, Department of Internal MedicineGazi UniversityAnkaraTurkey
  3. 3.Department of PathologyGazi UniversityAnkaraTurkey
  4. 4.Hacettepe University School of MedicineAnkaraTurkey

Personalised recommendations